- Home
- QH vs BOLD Comparison
QH vs BOLD Comparison
Compare QH & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QH
- BOLD
- Stock Information
- Founded
- QH 2012
- BOLD 2018
- Country
- QH China
- BOLD United States
- Employees
- QH N/A
- BOLD N/A
- Industry
- QH Business Services
- BOLD
- Sector
- QH Consumer Discretionary
- BOLD
- Exchange
- QH Nasdaq
- BOLD Nasdaq
- Market Cap
- QH 104.9M
- BOLD 30.3M
- IPO Year
- QH 2020
- BOLD 2024
- Fundamental
- Price
- QH $1.23
- BOLD $1.07
- Analyst Decision
- QH
- BOLD Buy
- Analyst Count
- QH 0
- BOLD 3
- Target Price
- QH N/A
- BOLD $4.00
- AVG Volume (30 Days)
- QH 7.5K
- BOLD 364.4K
- Earning Date
- QH 04-29-2025
- BOLD 08-11-2025
- Dividend Yield
- QH N/A
- BOLD N/A
- EPS Growth
- QH N/A
- BOLD N/A
- EPS
- QH 0.01
- BOLD N/A
- Revenue
- QH $417,431,053.00
- BOLD N/A
- Revenue This Year
- QH N/A
- BOLD N/A
- Revenue Next Year
- QH N/A
- BOLD N/A
- P/E Ratio
- QH $134.71
- BOLD N/A
- Revenue Growth
- QH N/A
- BOLD N/A
- 52 Week Low
- QH $0.25
- BOLD $1.00
- 52 Week High
- QH $2.27
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- QH 52.11
- BOLD N/A
- Support Level
- QH $1.16
- BOLD N/A
- Resistance Level
- QH $1.30
- BOLD N/A
- Average True Range (ATR)
- QH 0.04
- BOLD 0.00
- MACD
- QH 0.02
- BOLD 0.00
- Stochastic Oscillator
- QH 51.22
- BOLD 0.00
About QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.